Britain and America have agreed to a major bilateral deal that will guarantee zero levies on UK pharmaceutical exports being sold in the US market.
Key Provisions of the Accord
In exchange for the tariff guarantee, the UK has committed to raise expenditure on pharmaceuticals through the National Health Service (NHS). This commitment guarantees that import taxes on these crucial exports will stay at nothing for a duration of three years.
This development follows recent warnings to significantly raise tariffs on patented pharmaceutical products, with potential rates mentioned as high as one hundred percent.
"This agreement between the UK reinforces the worldwide climate for innovative medicines and establishes long-overdue fairness to American-British pharmaceutical trade," a release noted.
Trade Impact
Drugs are one of the Britain's most significant export categories to the America, which is easily the primary buyer for major UK drugmakers.
Export figures reveal that in the 12 months leading up to September, the UK exported drugs valued at over eleven billion pounds to the US. This value represented 17.4% of British export trade in that timeframe.
"This guarantee safeguards jobs, boosts funding and sets the stage for the UK to emerge as a worldwide center for medical research," the Business and Trade Secretary commented.
Specific UK Commitments
The agreement includes several key changes from the United Kingdom:
- Price Threshold Increase: The UK will raise the affordability limit at which it deems new medicines to be too expensive by twenty-five percent.
- Boosted Medicine Funding: There is a goal to raise overall health service expenditure on drugs from 0.3 percent of GDP to 0.6 percent over the coming ten years.
- Rebate Cap: The amount drug companies must refund to the NHS to control costs will be limited at 15%. Last year, repayments exceeded twenty percent.
Industry Background
The deal comes amid a protracted tension between the drug companies and the UK government over spending levels and NHS adoption.
These tensions were exacerbated by claims that American customers were paying significantly more for the same drugs than patients in the other developed nations.
Recently, several significant drug company projects in the UK have been delayed or abandoned, while major investments have been pledged toward projects in the United States.
The Science Minister acknowledged that the NHS needed to increase expenditure on drugs, noting that its budget allocation on drugs had declined as a percentage of its total funding over the last ten years.
